Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH).
Conditions
Interventions
Trade Name: Crestor Film-Coated Tablet
Product Name: Crestor
Product Code: ZD4522
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Rosuvastatin calcium
CAS Number: 147098-20-2
Concentratio
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Prior to any study related procedures being performed, provision of written informed consent from a parent/both parents or guardian and statement of assent from the child or adolescent (if required by Institutional Review Board [IRB] or Independent Ethics Committee [IEC] according to local regulations and guidelines). Study D3561C00004 participants who have had their 18th birthday (adults) will be required to provide written informed consent. Communication should take place between the Investigator, patient/guardian and child/adolescent to confirm understanding and required compliance with the requirements of the study; 2. Male and female children and adolescents who were aged 6 to 500 mg/dL (12.9 mmol/L) and TG =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. History of statin inducted myopathy or serious hypersensitivity reaction to other HMG CoA reductase inhibitors (statins), including rosuvastatin, at Visit 1 of Study D3561C00004; 2. Fasting serum glucose of >9.99 mmol/L (180 mg/dL) or glycosylated hemoglobin >9% during Study D3561C00004 or patients with a history of diabetic ketoacidosis within the past year; 3. Uncontrolled hypothyroidism defined as thyroid stimulating hormone >1.5 times the upper limit of normal (ULN) at any time during Study D3561C00004; 4. Evidence of active liver disease or hepatic dysfunction (except a confirmed diagnosis of Gilbert’s disease) as defined as non-transient elevations of ALT or AST elevations =3 times the ULN or non-transient total bilirubin =2 times the ULN during the Study D3561C00004; 5. Serum CK ?3 times ULN (unless transient and/or explained by exercise) during Study D3561C00004; 6. Estimated glomerular filtration rate by Schwartz formula <50 mL/min at Visit 1 of Study D3561C00004; 7. A non-transient finding of =2 + proteinuria on urine dipstick during Study D3561C00004; 8. Stage 2 hypertension (non-transient systolic and/or diastolic blood pressure greater than 5 mmHg above the 99th percentile for age, gender, and height) during Study D3561C00004; 9. History of solid organ transplantation reported at any time; 10. Involvement in the planning and/or conduct of this study (applies to both AstraZeneca staff and/or staff at the study site); 11. Previous withdrawal from the present study; 12. Participation in clinical study (other than Study D3561C00004) where an investigational product was ingested within 30 days prior to the current study; 13. At the discretion of the Investigator: any new and clinically significant abnormalities in medical history, chemistry, hematology, or urinalysis results; 14. Definite or suspected personal history or family history of clinically significant adverse drug reactions (ADRs), or hypersensitivity to drugs with a similar chemical structure to rosuvastatin as well as other statins; 15. History or presence of gastrointestinal, hepatic, or renal disease or other conditions known to interfere with absorption, distribution, metabolism, or excretion of drugs; 16. Treatment in the previous 3 months with any drug known to have a well defined potential for hepatotoxicity (e.g., halothane); 17. Clinical judgment by the Investigator that the patient should not participate in the study; 18. Patients weighing <20 kg (44 lbs) or; 19. Pregnancy or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the long-term safety and tolerability of rosuvastatin 20 mg in pediatric patients with Homozygous Familial Hypercholesterolemia (HoFH).;Secondary Objective: Not applicable;Primary end point(s): Safety Adverse events, including: • The frequency and severity of adverse events, • Rate of discontinuations due to adverse events, • Abnormal serum and urine laboratory values, electrocardiograms (ECGs), physical examinations, and vital signs; and Assessments of growth, including height (linear growth [cm and standard deviation (SD) score]), weight, and secondary characteristics of sexual maturation by Tanner stage performed at Visit 1 (as part of the final assessments of Study D3561C00004), Visit 5, and the final visit of Study D356NC00001 (at least annually). ;Timepoint(s) of evaluation of this end point: Samples taken at week 0, week 12, week 24, week 36, week 48, week 60, week 72, week 84, week 96 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Efficacy Low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides (TG), non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, apolipoprotein B (ApoB), apolipoprotein A-1 (ApoA 1), and ApoB/ApoA-1 at 12-week intervals during treatment with rosuvastatin 20 mg.;Timepoint(s) of evaluation of this end point: Samples taken at week 0, week 12, week 24, week 36, week 48, week 60, week 72, week 84, week 96 | — |
Countries
Belgium, Canada, Denmark, Germany, Israel, Lebanon, Malaysia, Netherlands, Sweden, Taiwan, United States
Contacts
Public ContactInformation Centre
AstraZeneca
Outcome results
None listed